Macitentan/tadalafil - Acetelion

Drug Profile

Macitentan/tadalafil - Acetelion

Alternative Names: Tadalafil /Macitentan

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antifibrotics; Antihypertensives; Antineoplastics; Benzodioxoles; Bromobenzenes; Carbolines; Cardiovascular therapies; Erectile dysfunction therapies; Indoles; Pyrimidines; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 24 Sep 2017 Actelion completes a phase I trial in Pulmonary arterial hypertension (In volunteers) in Germany (PO) (NCT03215966)
  • 07 Aug 2017 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in Germany (PO) (NCT03215966)
  • 17 Jul 2017 Preclinical trials in Pulmonary arterial hypertension in Switzerland (PO) (NCT03215966) before July 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top